NG BIOTECH
Sebastien Quesney has extensive experience in various roles within the biotechnology and diagnostic industries. Sebastien currently serves as the Chief Technology Officer at NG BIOTECH since 2022. Prior to this, they worked at Institut Pasteur from 2019 to 2022, where they held the positions of Deputy Director of the innovative diagnostic test and development core facility and Head of Diagnostic Innovation Development. From 2014 to 2019, Quesney was the Director of Access to Diagnosis -Neglected Diseases- at Fondation Mérieux. Before that, they held multiple roles at IMACCESS, including General Manager and Project Executive R&D Director. Quesney also served as the R&D Director at Magnisense SE from 2007 to 2012. Sebastien began their career at bioMerieux as a Production Manager from 2002 to 2007 and worked as a Researcher at Sanofi Pasteur from 1998 to 2002.
Sebastien Quesney holds a PhD from Université Claude Bernard Lyon 1 and a DEA in Biochimie et Biologie Cellulaire from Université de Mont Saint Aignan, Rouen.
This person is not in any teams
This person is not in any offices
NG BIOTECH
At NG Biotech, we develop, manufacture and commercialise rapid, mobile and connected diagnostics to modernize diagnosis practice worldwide. NG Biotech is a French company specialized in Research & Development, Manufacturing and Marketing of a new generation of "multiplex", "quantitative" and "connected" rapid diagnostics for biomarker analysis and/or therapy monitoring at the Point of Care. NG Biotech’s patented platform is rapid, mobile and connected. It allows to simultaneously analyse up to 9 biomarkers from a biological direct sample such as a single finger-prick drop of blood. The results can be sent via smartphone within five minutes. NG Biotech commercializes a range of rapid diagnostic devices covering antimicrobial resistance, women’s health and infectious disease. NG Biotech also proposes custom development partnerships with further manufacturing to support breakthrough innovative ideas with rapid diagnostic needs. Backed by a strong R&D team and 30 years of know-how, NG-Biotech is always at the hedge of technology and can conduct projects from feasibility stage up to CE marking and FDA clearance.